Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 149

Sort by

Sort Order Select

Journal Articles

Characterization of Community-Based Socioeconomic Factors, Utilization, and Adherence in Children with Sickle Cell Disease

Ronay Thomas, BS, Patrick T. McGann, MD, Andrew Beck, MD MPH, Amanda Pfeiffer, Kyesha M James, BS

Blood (2019) 134 (Supplement_1): 4686.

https://doi.org/10.1182/blood-2019-130637

Published: 2019

Journal Articles

Resistance to Acalabrutinib in CLL Is Mediated Primarily By BTK Mutations

Jennifer Woyach, MD, Ying Huang, MS, MA, Kerry Rogers, Seema A. Bhat, MD, Michael R. Grever, MD, Arletta Lozanski, Tzyy-Jye Doong, James S. Blachly, MD, Gerard Lozanski, MD, Dan Jones, MD PhD, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 504.

https://doi.org/10.1182/blood-2019-127674

Published: 2019

Journal Articles

The Effect of Cytogenetic Abnormalities on Organ Involvement and Survival in Patients with AL Amyloidosis

Michael Ozga, MD, Qiuhong Zhao, MS, Don M. Benson, Jr., MD PhD, Patrick Elder, MS, Nita Williams, Naresh Bumma, MD, Ashley E. Rosko, MD, Maria Chaudhry, MD, Abdullah Mohammad Khan, MBBS,MSc, Srinivas Devarakonda, MD, Rami Kahwash, MD, Ajay Vallakati, MD, Courtney Campbell, MD PhD, Samir Parikh, MD, Salem Almaani, MD, Jason Prosek, MD, Elyse Redder, PT, CLT-LANA, Yvonne A. Efebera, MD MPH, Nidhi Sharma, PhD

Blood (2019) 134 (Supplement_1): 1833.

https://doi.org/10.1182/blood-2019-124206

Published: 2019

Journal Articles

Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

Jennifer Woyach, MD, Amy S. Ruppert, MAS, PhD, Gabriela Perez, MS, Allison M Booth, Diane Feldman, Elie G Dib, MD, Aminah Jatoi, MD, Jennifer Le-Rademacher, PhD, Nyla A. Heerema, PhD, Gerard Lozanski, MD, Richard Little, MD, Wei Ding, MD PhD, Brian T. Hill, MD, Richard M. Stone, MD, Sumithra J Mandrekar, PhD, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 1751.

https://doi.org/10.1182/blood-2019-127102

Published: 2019

Journal Articles

Final Results of a Phase 2 Trial of Early Intervention Ibrutinib with Vaccinations in Patients with Asymptomatic, High-Risk CLL

Jennifer Woyach, MD, Shanmugapriya Thangavadivel, PhD, David Weiss, Lai Wei, PhD, Eric McLaughlin, MS, Kerry Rogers, Seema A. Bhat, MD, Michael R. Grever, MD, Michael Keller, Matthew Dort, Gerard Lozanski, MD, Barbara Andersen, PhD, John C. Byrd, MD, Farrukh T. Awan, MD

Blood (2019) 134 (Supplement_1): 1759.

https://doi.org/10.1182/blood-2019-131099

Published: 2019

Journal Articles

ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL)

Blood (2019) 134 (Supplement_1): 31.

https://doi.org/10.1182/blood-2019-128404

Published: 2019

Journal Articles

Identification of Novel Synthetic Lethal Partners of NAMPT Inhibitor By CRISPR-Cas9 Screens in Acute Myeloid Leukemia

Pu Zhang, Lindsey Brinton, PhD, James S. Blachly, MD, John C. Byrd, MD, Rosa Lapalombella, PhD

Blood (2019) 134 (Supplement_1): 2072.

https://doi.org/10.1182/blood-2019-129036

Published: 2019

Journal Articles

The Protein Kinase C Inhibitor MS-553 for the Treatment of Chronic Lymphocytic Leukemia

Elizabeth M. Muhowski, Amy M. Lehman, M.A.S, Sean D. Reiff, PhD, Janani Ravikrishnan, Rose Mantel, Shrilekha Misra, Michael Niesman, PhD, Kai Zhang, MD, James S. Blachly, MD, Deepa Sampath, PhD, John C. Byrd, MD, Jennifer Woyach, MD

Blood (2019) 134 (Supplement_1): 2077.

https://doi.org/10.1182/blood-2019-128871

Published: 2019

Journal Articles

AL Amyloidosis: The Effects of Maintenance Therapy on Autologous Stem Cell Transplantation Outcomes

Blood (2019) 134 (Supplement_1): 2029.

https://doi.org/10.1182/blood-2019-130307

Published: 2019

Journal Articles

Newly Diagnosed AML Patient Samples Demonstrate High Degree of Concordance in Identification of Pathogenic Mutations By Next Generation Sequencing (NGS) Performed at Enrolling Institutions Compared to Central Laboratory Results in the Beat AML Master Trial

Blood (2019) 134 (Supplement_1): 2145.

https://doi.org/10.1182/blood-2019-131253

Published: 2019

Journal Articles

Concurrent Treatment of VEGFR Tyrosine Kinase Inhibitors (TKIs) and Factor Xa Inhibitors Is Associated with Increased Bleeding Risks

Sandip Patel, MBBS, Tiffany George, MD, Tzu-Fei Wang, MD MPH, Sherry Mori Vogt, Pharm D, Edmund Folefac, MD, Ming Yin, MD

Blood (2019) 134 (Supplement_1): 3681.

https://doi.org/10.1182/blood-2019-130465

Published: 2019

Journal Articles

NPM1 mutations Using Deep Amplicon Sequencing and Broad Next Generation Sequencing at the Time of Complete Remission Is Informative to Predicting Risk of Relapse Following Intensive Chemotherapy

Bhavana Bhatnagar, DO, Shelley Orwick, BS, Nyla A. Heerema, PhD, Alison R. Walker, MD, Alice S. Mims, MD, James S. Blachly, MD, Karilyn Larkin, MD, Nicole Grieselhuber, MD PhD, Gregory K. Behbehani, MD PhD, Apollinaire Ngankeu, Charles Thomas Gregory, BS, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 1329.

https://doi.org/10.1182/blood-2019-130856

Published: 2019

Journal Articles

Alliance A041701 - a Randomized Phase 2/3 Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia (AML) Receiving Intensive Induction Chemotherapy

Geoffrey L. Uy, MD, Jun Yin, PhD, Heidi D. Klepin, MD, Shira Dinner, MD, Anthony J. Jaslowski, MD, Stephen A. Strickland, MD, Jane L. Liesveld, MD, John C. Byrd, MD, Richard M. Stone, MD

Blood (2019) 134 (Supplement_1): 1366.

https://doi.org/10.1182/blood-2019-127142

Published: 2019

Journal Articles

DNA Methylation-Based Classification Highlights the Role of the JAK-STAT Pathway in Acute Myeloid Leukemia

Brian Giacopelli, BS, Min Wang, Ada C Cleary, Yue-zhong Wu, MSc, Anna Reister Schultz, James S. Blachly, MD, Ann-Kathrin Eisfeld, MD, Kevin R Coombes, Clara D. Bloomfield, MD, Brian J. Druker, Jeffrey W. Tyner, John C. Byrd, MD, Christopher C. Oakes, PhD

Blood (2019) 134 (Supplement_1): 1413.

https://doi.org/10.1182/blood-2019-126212

Published: 2019

Journal Articles

Rapid Dose Escalation of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with B-Cell Receptor Inhibitor Therapy

Kristin Koenig, MD, Emily Dotson, PharmD, Shane Sheredy, Seema A. Bhat, MD, John C. Byrd, MD, Tracy Wiczer, Jennifer Woyach, MD, Farrukh T. Awan, MD, Kerry A. Rogers, MD

Blood (2019) 134 (Supplement_1): 3045.

https://doi.org/10.1182/blood-2019-124538

Published: 2019

Journal Articles

A Multicenter Study of Ibrutinib Resistance Development and Intervention with Venetoclax in Patients with Chronic Lymphocytic Leukemia

Kerry A Rogers, MD, Lai Wei, PhD, Seema A. Bhat, MD, Dan Jones, MD PhD, Erlene K. Seymour, MD, Deborah M. Stephens, DO, J Christine Ye, MDMSc, John C. Byrd, MD, Jennifer Woyach, MD

Blood (2019) 134 (Supplement_1): 3049.

https://doi.org/10.1182/blood-2019-125360

Published: 2019

Journal Articles

Developmental DNA Methylation Subtype Predicts Progression to Treatment and Survival in High-Count Monoclonal B Lymphocytosis

Brian Giacopelli, BS, Kari G. Chaffee, MS, Yue-zhong Wu, MSc, John C. Byrd, MD, Tait D. Shanafelt, MD, Sameer A. Parikh, MD, Esteban Braggio, PhD, Susan L. Slager, PhD, Neil E. Kay, MD, Christopher C. Oakes, PhD

Blood (2019) 134 (Supplement_1): 3022.

https://doi.org/10.1182/blood-2019-123564

Published: 2019

Journal Articles

BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression

Paul J. Hampel, MD, Timothy G. Call, MD, Sara J. Achenbach, Kari G Rabe, Wei Ding, MD PhD, Eli Muchtar, MD, Saad S. Kenderian, MD, Yucai Wang, MD PhD, Amber Koehler, PA-C, MS, Amie Fonder, PA-C, MS, Jose F. Leis, MD PhD, Susan M. Schwager, Daniel L. Van Dyke, PhD, Esteban Braggio, PhD, Susan L. Slager, PhD, Neil E. Kay, MD, Sameer A. Parikh, MD

Blood (2019) 134 (Supplement_1): 3050.

https://doi.org/10.1182/blood-2019-125411

Published: 2019

Journal Articles

Using Ibrutinib in Earlier Lines of Treatment Results in Better Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Paul M. Barr, MD, Alessandra Tedeschi, MD, Talha Munir, MD, Peter Hillmen, MD PhD, Jennifer Woyach, MD, John C. Byrd, MD, Paolo Ghia, MD PhD, Stephen Mulligan, MBBS, MD FRACP, FRCPA, Sandra Dai, PhD MS, Carlos Amaya-Chanaga, MD, James P. Dean, MD PhD, Susan M. o'Brien, MD

Blood (2019) 134 (Supplement_1): 3054.

https://doi.org/10.1182/blood-2019-123327

Published: 2019

Journal Articles

Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study

Blood (2019) 134 (Supplement_1): 3039.

https://doi.org/10.1182/blood-2019-128706

Published: 2019

NARROW

Characterization of Community-Based Socioeconomic Factors, Utilization, and Adherence in Children with Sickle Cell Disease

Resistance to Acalabrutinib in CLL Is Mediated Primarily By BTK Mutations

The Effect of Cytogenetic Abnormalities on Organ Involvement and Survival in Patients with AL Amyloidosis

Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

Final Results of a Phase 2 Trial of Early Intervention Ibrutinib with Vaccinations in Patients with Asymptomatic, High-Risk CLL

ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL)

Identification of Novel Synthetic Lethal Partners of NAMPT Inhibitor By CRISPR-Cas9 Screens in Acute Myeloid Leukemia

The Protein Kinase C Inhibitor MS-553 for the Treatment of Chronic Lymphocytic Leukemia

AL Amyloidosis: The Effects of Maintenance Therapy on Autologous Stem Cell Transplantation Outcomes

Newly Diagnosed AML Patient Samples Demonstrate High Degree of Concordance in Identification of Pathogenic Mutations By Next Generation Sequencing (NGS) Performed at Enrolling Institutions Compared to Central Laboratory Results in the Beat AML Master Trial

Concurrent Treatment of VEGFR Tyrosine Kinase Inhibitors (TKIs) and Factor Xa Inhibitors Is Associated with Increased Bleeding Risks

NPM1 mutations Using Deep Amplicon Sequencing and Broad Next Generation Sequencing at the Time of Complete Remission Is Informative to Predicting Risk of Relapse Following Intensive Chemotherapy

Alliance A041701 - a Randomized Phase 2/3 Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia (AML) Receiving Intensive Induction Chemotherapy

DNA Methylation-Based Classification Highlights the Role of the JAK-STAT Pathway in Acute Myeloid Leukemia

Rapid Dose Escalation of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with B-Cell Receptor Inhibitor Therapy

A Multicenter Study of Ibrutinib Resistance Development and Intervention with Venetoclax in Patients with Chronic Lymphocytic Leukemia

Developmental DNA Methylation Subtype Predicts Progression to Treatment and Survival in High-Count Monoclonal B Lymphocytosis

BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression

Using Ibrutinib in Earlier Lines of Treatment Results in Better Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only